Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs
| Autor: | M. Krautmann, J. Messamore, P. Cole, L.M. Bergeron, Rai Sharath K, K. Saad, J. Tena, Martin Guillot, L. Chouinard, Duncan Mwangi, Paul J. Dominowski, R. Walters, Y. Zhu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Agonist
medicine.medical_specialty medicine.drug_class Pharmacology Tropomyosin receptor kinase A Monoclonal antibody Receptor Nerve Growth Factor Dogs Nerve Growth Factor medicine Low-affinity nerve growth factor receptor Animals Carprofen General Veterinary biology Clinical pathology business.industry Antibodies Monoclonal Nerve growth factor biology.protein Animal Science and Zoology Antibody business Laboratories medicine.drug Signal Transduction |
| Zdroj: | Veterinary journal (London, England : 1997). 276 |
| ISSN: | 1532-2971 |
| Popis: | Nerve growth factor (NGF), a critical mediator of nociception, is a novel analgesic therapeutic target. Bedinvetmab, a canine monoclonal antibody (mAb), binds NGF and inhibits its interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. The objective of three integrated laboratory studies was to demonstrate the safety of bedinvetmab in adult laboratory Beagle dogs. Daily health, veterinary, clinical pathology, systemic exposure, and anti-drug antibody evaluations were performed. Study 1 additionally included electrocardiography, neurologic, and ophthalmic assessments, and radiographic monitoring of joints of the appendicular skeleton. Study 2 evaluated T-lymphocyte-dependent immune function. Study 3 evaluated the safety of short-term concurrent administration of carprofen, a nonsteroidal anti-inflammatory drug (NSAID), with bedinvetmab. Studies 1 and 3 included terminal pathology and histopathology evaluations. Study designs and procedures included directed complementary morphologic and functional evaluations of a literature- and in vitro-based list of potential safety issues related to the NGF signaling pathway and characteristics engineered into this mAb. Screening-level general procedures evaluated effects associated with mAbs that target and inhibit soluble agonist cytokines. There were no treatment-related adverse changes in clinical evaluations, clinical neurological and ophthalmic examinations, joints, immune morphology or function, and no effects of short-term concurrent NSAID usage. Treatment-emergent immunogenicity was not observed. Bedinvetmab (1 mg/kg SC monthly; 3× and 10× dose multiples) was well tolerated in normal laboratory Beagle dogs for 6 months and with 2 weeks’ concurrent NSAID administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect